391 related articles for article (PubMed ID: 33915463)
21. Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Walker AR; Wang H; Walsh K; Bhatnagar B; Vasu S; Garzon R; Canning R; Geyer S; Wu YZ; Devine SM; Klisovic R; Blum W; Marcucci G
Leuk Lymphoma; 2016 Sep; 57(9):2100-8. PubMed ID: 26784138
[TBL] [Abstract][Full Text] [Related]
22. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.
Holkova B; Shafer D; Yazbeck V; Dave S; Bose P; Tombes MB; Shrader E; Wan W; Bandyopadhyay D; Weir C; Collins EB; Garnett A; Kmieciak M; Roberts JD; Garcia-Manero G; Grant S
Leuk Lymphoma; 2021 May; 62(5):1187-1194. PubMed ID: 33356689
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
25. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
[TBL] [Abstract][Full Text] [Related]
26. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
[TBL] [Abstract][Full Text] [Related]
27. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
[TBL] [Abstract][Full Text] [Related]
28. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Lancet JE; Gojo I; Gotlib J; Feldman EJ; Greer J; Liesveld JL; Bruzek LM; Morris L; Park Y; Adjei AA; Kaufmann SH; Garrett-Mayer E; Greenberg PL; Wright JJ; Karp JE
Blood; 2007 Feb; 109(4):1387-94. PubMed ID: 17082323
[TBL] [Abstract][Full Text] [Related]
29. Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.
Epling-Burnette PK; Loughran TP
Expert Opin Investig Drugs; 2010 May; 19(5):689-98. PubMed ID: 20402600
[TBL] [Abstract][Full Text] [Related]
30. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
31. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
Cooper TM; Sison EAR; Baker SD; Li L; Ahmed A; Trippett T; Gore L; Macy ME; Narendran A; August K; Absalon MJ; Boklan J; Pollard J; Magoon D; Brown PA
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28409853
[TBL] [Abstract][Full Text] [Related]
32. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.
Fenaux P; Raza A; Mufti GJ; Aul C; Germing U; Kantarjian H; Cripe L; Kerstens R; De Porre P; Kurzrock R
Blood; 2007 May; 109(10):4158-63. PubMed ID: 17264294
[TBL] [Abstract][Full Text] [Related]
33. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
35. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.
Harousseau JL; Lancet JE; Reiffers J; Lowenberg B; Thomas X; Huguet F; Fenaux P; Zhang S; Rackoff W; De Porre P; Stone R;
Blood; 2007 Jun; 109(12):5151-6. PubMed ID: 17351110
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Cortes J; Quintás-Cardama A; Garcia-Manero G; O'Brien S; Jones D; Faderl S; Ebarb T; Giles F; Thomas D; Kantarjian H
Cancer; 2007 Nov; 110(9):2000-6. PubMed ID: 17849425
[TBL] [Abstract][Full Text] [Related]
37. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
38. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Braun T; Fenaux P
Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
[TBL] [Abstract][Full Text] [Related]
39. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Karp JE; Flatten K; Feldman EJ; Greer JM; Loegering DA; Ricklis RM; Morris LE; Ritchie E; Smith BD; Ironside V; Talbott T; Roboz G; Le SB; Meng XW; Schneider PA; Dai NT; Adjei AA; Gore SD; Levis MJ; Wright JJ; Garrett-Mayer E; Kaufmann SH
Blood; 2009 May; 113(20):4841-52. PubMed ID: 19109557
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of bortezomib in refractory or relapsed acute leukemias.
Cortes J; Thomas D; Koller C; Giles F; Estey E; Faderl S; Garcia-Manero G; McConkey D; Ruiz SL; Guerciolini R; Wright J; Kantarjian H
Clin Cancer Res; 2004 May; 10(10):3371-6. PubMed ID: 15161691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
